1150TiP A phase II, open-label, multi-dose study of [89Zr]Zr-Df-IAB22M2C (CD8 cell PET tracer) PET/CT in patients with selected advanced or metastatic solid malignancies scheduled to receive standard of care immunotherapy, as single agent or in combination

Autor:	Margolin, K.A., Korn, R., Farwell, M., Postow, M.A., Hays, D., Wilson, I.A., Le, W.H.
Zdroj:	In Annals of Oncology September 2021 32 Supplement 5:S930-S930
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu